Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis
GlycA is a novel inflammatory biomarker measured using nuclear magnetic resonance (NMR). Its NMR signal primarily represents glycosylated acute phase proteins. GlycA was associated with inflammation and development of cardiovascular disease in initially healthy women. We hypothesized that GlycA is a...
Gespeichert in:
| Veröffentlicht in: | Arthritis research & therapy 2015-05, Vol.17 (1), p.117-117, Article 117 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 117 |
|---|---|
| container_issue | 1 |
| container_start_page | 117 |
| container_title | Arthritis research & therapy |
| container_volume | 17 |
| creator | Ormseth, Michelle J Chung, Cecilia P Oeser, Annette M Connelly, Margery A Sokka, Tuulikki Raggi, Paolo Solus, Joseph F Otvos, James D Stein, C Michael |
| description | GlycA is a novel inflammatory biomarker measured using nuclear magnetic resonance (NMR). Its NMR signal primarily represents glycosylated acute phase proteins. GlycA was associated with inflammation and development of cardiovascular disease in initially healthy women. We hypothesized that GlycA is a biomarker of disease activity and is associated with coronary artery atherosclerosis in patients with rheumatoid arthritis (RA).
We conducted a cross-sectional study of 166 patients with RA and 90 control subjects. GlycA was measured from an NMR signal originating from N-acetylglucosamine residues on circulating glycoproteins. The relationship between GlycA and RA disease activity (Disease Activity Score based on 28 joints (DAS28)) and coronary artery calcium score was determined.
GlycA concentrations were higher in patients with RA (median (interquartile range): 398 μmol/L (348 to 473 μmol/L)) than control subjects (344 μmol/L (314 to 403 μmol/L) (P |
| doi_str_mv | 10.1186/s13075-015-0646-x |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4445500</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541613711</galeid><sourcerecordid>A541613711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c606t-e3d329c498cb702db9582a880bad0754a7da7914b08b7f535eefccfbe6f78963</originalsourceid><addsrcrecordid>eNptUk1r3DAUNKWlSdP-gF6KoJcc4kSy9WFfCkto00Cgl-QsnuWnrFrZSiXtkj33j1dm06WBICQ9pJnhvWGq6iOj54x18iKxlipRU1a25LJ-fFUdM666WrayeX2oBT-q3qX0k9Km6Rv-tjpqRC9kKY-rP3fZeZd3JFgCZA5b9MTN1sM0QQ5xRyaIvzCekSu_M6szYkMkkBKmNOGcF1Zc42bBupFAzOvosktkdAkhIQGT3XaRh3kkJsQwQ9GEvMYYkvHL6dL76o0Fn_DD031S3X77env5vb75cXV9ubqpjaQy19iObdMb3ndmULQZh150DXQdHWAsNnBQI6ie8YF2g7KiFYjWGDugtKrrZXtSfdnLPmyGCUdT-o_g9UN0ZcadDuD085_ZrfV92GrOuRCUFoHTJ4EYfm8wZT25ZNB7mDFskmay47zplRIF-nkPvQePuhgaiqJZ4HolOJOsVYwV1PkLqLJGnJwJM1pX3p8R2J5ginEpoj10z6heIqH3kdAlEnqJhH4snE__j31g_MtA-xflHrWW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1684429775</pqid></control><display><type>article</type><title>Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Ormseth, Michelle J ; Chung, Cecilia P ; Oeser, Annette M ; Connelly, Margery A ; Sokka, Tuulikki ; Raggi, Paolo ; Solus, Joseph F ; Otvos, James D ; Stein, C Michael</creator><creatorcontrib>Ormseth, Michelle J ; Chung, Cecilia P ; Oeser, Annette M ; Connelly, Margery A ; Sokka, Tuulikki ; Raggi, Paolo ; Solus, Joseph F ; Otvos, James D ; Stein, C Michael</creatorcontrib><description>GlycA is a novel inflammatory biomarker measured using nuclear magnetic resonance (NMR). Its NMR signal primarily represents glycosylated acute phase proteins. GlycA was associated with inflammation and development of cardiovascular disease in initially healthy women. We hypothesized that GlycA is a biomarker of disease activity and is associated with coronary artery atherosclerosis in patients with rheumatoid arthritis (RA).
We conducted a cross-sectional study of 166 patients with RA and 90 control subjects. GlycA was measured from an NMR signal originating from N-acetylglucosamine residues on circulating glycoproteins. The relationship between GlycA and RA disease activity (Disease Activity Score based on 28 joints (DAS28)) and coronary artery calcium score was determined.
GlycA concentrations were higher in patients with RA (median (interquartile range): 398 μmol/L (348 to 473 μmol/L)) than control subjects (344 μmol/L (314 to 403 μmol/L) (P < 0.001). In RA, GlycA was strongly correlated with DAS28 based on erythrocyte sedimentation rate (DAS28-ESR) and DAS28 based on C-reactive protein (DAS28-CRP) and their components, including tender and swollen joint counts, global health score, ESR and CRP (all P < 0.001). The area under the receiver operating characteristic curve for GlycA's ability to differentiate between patients with low versus moderate to high disease activity based on DAS28-CRP was 0.75 (95% confidence interval (CI): 0.68, 0.83). For each quartile increase in GlycA, the odds of having coronary artery calcium increased by 48% (95% CI: 4%, 111%), independent of age, race and sex (P = 0.03).
GlycA is a novel inflammatory marker that may be useful for assessment of disease activity and is associated with coronary artery atherosclerosis in patients with RA.</description><identifier>ISSN: 1478-6354</identifier><identifier>EISSN: 1478-6362</identifier><identifier>EISSN: 1478-6354</identifier><identifier>DOI: 10.1186/s13075-015-0646-x</identifier><identifier>PMID: 25956924</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Area Under Curve ; Arthritis ; Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - pathology ; Atherosclerosis ; Biomarkers - analysis ; Blood ; C-reactive protein ; Cardiovascular diseases ; Coronary Artery Disease - etiology ; Coronary Artery Disease - pathology ; Cross-Sectional Studies ; Diagnosis ; Female ; Glycoproteins ; Health aspects ; Humans ; Inflammation ; Magnetic Resonance Spectroscopy - methods ; Male ; Medical examination ; Medical research ; Medicine, Experimental ; Middle Aged ; Rheumatoid factor ; Risk factors ; ROC Curve</subject><ispartof>Arthritis research & therapy, 2015-05, Vol.17 (1), p.117-117, Article 117</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>Ormseth et al.; licensee BioMed Central. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c606t-e3d329c498cb702db9582a880bad0754a7da7914b08b7f535eefccfbe6f78963</citedby><cites>FETCH-LOGICAL-c606t-e3d329c498cb702db9582a880bad0754a7da7914b08b7f535eefccfbe6f78963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445500/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445500/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25956924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ormseth, Michelle J</creatorcontrib><creatorcontrib>Chung, Cecilia P</creatorcontrib><creatorcontrib>Oeser, Annette M</creatorcontrib><creatorcontrib>Connelly, Margery A</creatorcontrib><creatorcontrib>Sokka, Tuulikki</creatorcontrib><creatorcontrib>Raggi, Paolo</creatorcontrib><creatorcontrib>Solus, Joseph F</creatorcontrib><creatorcontrib>Otvos, James D</creatorcontrib><creatorcontrib>Stein, C Michael</creatorcontrib><title>Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis</title><title>Arthritis research & therapy</title><addtitle>Arthritis Res Ther</addtitle><description>GlycA is a novel inflammatory biomarker measured using nuclear magnetic resonance (NMR). Its NMR signal primarily represents glycosylated acute phase proteins. GlycA was associated with inflammation and development of cardiovascular disease in initially healthy women. We hypothesized that GlycA is a biomarker of disease activity and is associated with coronary artery atherosclerosis in patients with rheumatoid arthritis (RA).
We conducted a cross-sectional study of 166 patients with RA and 90 control subjects. GlycA was measured from an NMR signal originating from N-acetylglucosamine residues on circulating glycoproteins. The relationship between GlycA and RA disease activity (Disease Activity Score based on 28 joints (DAS28)) and coronary artery calcium score was determined.
GlycA concentrations were higher in patients with RA (median (interquartile range): 398 μmol/L (348 to 473 μmol/L)) than control subjects (344 μmol/L (314 to 403 μmol/L) (P < 0.001). In RA, GlycA was strongly correlated with DAS28 based on erythrocyte sedimentation rate (DAS28-ESR) and DAS28 based on C-reactive protein (DAS28-CRP) and their components, including tender and swollen joint counts, global health score, ESR and CRP (all P < 0.001). The area under the receiver operating characteristic curve for GlycA's ability to differentiate between patients with low versus moderate to high disease activity based on DAS28-CRP was 0.75 (95% confidence interval (CI): 0.68, 0.83). For each quartile increase in GlycA, the odds of having coronary artery calcium increased by 48% (95% CI: 4%, 111%), independent of age, race and sex (P = 0.03).
GlycA is a novel inflammatory marker that may be useful for assessment of disease activity and is associated with coronary artery atherosclerosis in patients with RA.</description><subject>Analysis</subject><subject>Area Under Curve</subject><subject>Arthritis</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - pathology</subject><subject>Atherosclerosis</subject><subject>Biomarkers - analysis</subject><subject>Blood</subject><subject>C-reactive protein</subject><subject>Cardiovascular diseases</subject><subject>Coronary Artery Disease - etiology</subject><subject>Coronary Artery Disease - pathology</subject><subject>Cross-Sectional Studies</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Glycoproteins</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Magnetic Resonance Spectroscopy - methods</subject><subject>Male</subject><subject>Medical examination</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Rheumatoid factor</subject><subject>Risk factors</subject><subject>ROC Curve</subject><issn>1478-6354</issn><issn>1478-6362</issn><issn>1478-6354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUk1r3DAUNKWlSdP-gF6KoJcc4kSy9WFfCkto00Cgl-QsnuWnrFrZSiXtkj33j1dm06WBICQ9pJnhvWGq6iOj54x18iKxlipRU1a25LJ-fFUdM666WrayeX2oBT-q3qX0k9Km6Rv-tjpqRC9kKY-rP3fZeZd3JFgCZA5b9MTN1sM0QQ5xRyaIvzCekSu_M6szYkMkkBKmNOGcF1Zc42bBupFAzOvosktkdAkhIQGT3XaRh3kkJsQwQ9GEvMYYkvHL6dL76o0Fn_DD031S3X77env5vb75cXV9ubqpjaQy19iObdMb3ndmULQZh150DXQdHWAsNnBQI6ie8YF2g7KiFYjWGDugtKrrZXtSfdnLPmyGCUdT-o_g9UN0ZcadDuD085_ZrfV92GrOuRCUFoHTJ4EYfm8wZT25ZNB7mDFskmay47zplRIF-nkPvQePuhgaiqJZ4HolOJOsVYwV1PkLqLJGnJwJM1pX3p8R2J5ginEpoj10z6heIqH3kdAlEnqJhH4snE__j31g_MtA-xflHrWW</recordid><startdate>20150509</startdate><enddate>20150509</enddate><creator>Ormseth, Michelle J</creator><creator>Chung, Cecilia P</creator><creator>Oeser, Annette M</creator><creator>Connelly, Margery A</creator><creator>Sokka, Tuulikki</creator><creator>Raggi, Paolo</creator><creator>Solus, Joseph F</creator><creator>Otvos, James D</creator><creator>Stein, C Michael</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150509</creationdate><title>Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis</title><author>Ormseth, Michelle J ; Chung, Cecilia P ; Oeser, Annette M ; Connelly, Margery A ; Sokka, Tuulikki ; Raggi, Paolo ; Solus, Joseph F ; Otvos, James D ; Stein, C Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c606t-e3d329c498cb702db9582a880bad0754a7da7914b08b7f535eefccfbe6f78963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analysis</topic><topic>Area Under Curve</topic><topic>Arthritis</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - pathology</topic><topic>Atherosclerosis</topic><topic>Biomarkers - analysis</topic><topic>Blood</topic><topic>C-reactive protein</topic><topic>Cardiovascular diseases</topic><topic>Coronary Artery Disease - etiology</topic><topic>Coronary Artery Disease - pathology</topic><topic>Cross-Sectional Studies</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Glycoproteins</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Magnetic Resonance Spectroscopy - methods</topic><topic>Male</topic><topic>Medical examination</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Rheumatoid factor</topic><topic>Risk factors</topic><topic>ROC Curve</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ormseth, Michelle J</creatorcontrib><creatorcontrib>Chung, Cecilia P</creatorcontrib><creatorcontrib>Oeser, Annette M</creatorcontrib><creatorcontrib>Connelly, Margery A</creatorcontrib><creatorcontrib>Sokka, Tuulikki</creatorcontrib><creatorcontrib>Raggi, Paolo</creatorcontrib><creatorcontrib>Solus, Joseph F</creatorcontrib><creatorcontrib>Otvos, James D</creatorcontrib><creatorcontrib>Stein, C Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arthritis research & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ormseth, Michelle J</au><au>Chung, Cecilia P</au><au>Oeser, Annette M</au><au>Connelly, Margery A</au><au>Sokka, Tuulikki</au><au>Raggi, Paolo</au><au>Solus, Joseph F</au><au>Otvos, James D</au><au>Stein, C Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis</atitle><jtitle>Arthritis research & therapy</jtitle><addtitle>Arthritis Res Ther</addtitle><date>2015-05-09</date><risdate>2015</risdate><volume>17</volume><issue>1</issue><spage>117</spage><epage>117</epage><pages>117-117</pages><artnum>117</artnum><issn>1478-6354</issn><eissn>1478-6362</eissn><eissn>1478-6354</eissn><abstract>GlycA is a novel inflammatory biomarker measured using nuclear magnetic resonance (NMR). Its NMR signal primarily represents glycosylated acute phase proteins. GlycA was associated with inflammation and development of cardiovascular disease in initially healthy women. We hypothesized that GlycA is a biomarker of disease activity and is associated with coronary artery atherosclerosis in patients with rheumatoid arthritis (RA).
We conducted a cross-sectional study of 166 patients with RA and 90 control subjects. GlycA was measured from an NMR signal originating from N-acetylglucosamine residues on circulating glycoproteins. The relationship between GlycA and RA disease activity (Disease Activity Score based on 28 joints (DAS28)) and coronary artery calcium score was determined.
GlycA concentrations were higher in patients with RA (median (interquartile range): 398 μmol/L (348 to 473 μmol/L)) than control subjects (344 μmol/L (314 to 403 μmol/L) (P < 0.001). In RA, GlycA was strongly correlated with DAS28 based on erythrocyte sedimentation rate (DAS28-ESR) and DAS28 based on C-reactive protein (DAS28-CRP) and their components, including tender and swollen joint counts, global health score, ESR and CRP (all P < 0.001). The area under the receiver operating characteristic curve for GlycA's ability to differentiate between patients with low versus moderate to high disease activity based on DAS28-CRP was 0.75 (95% confidence interval (CI): 0.68, 0.83). For each quartile increase in GlycA, the odds of having coronary artery calcium increased by 48% (95% CI: 4%, 111%), independent of age, race and sex (P = 0.03).
GlycA is a novel inflammatory marker that may be useful for assessment of disease activity and is associated with coronary artery atherosclerosis in patients with RA.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>25956924</pmid><doi>10.1186/s13075-015-0646-x</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-6354 |
| ispartof | Arthritis research & therapy, 2015-05, Vol.17 (1), p.117-117, Article 117 |
| issn | 1478-6354 1478-6362 1478-6354 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4445500 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; DOAJ Directory of Open Access Journals; PubMed Central; PubMed Central Open Access; Springer Nature OA Free Journals |
| subjects | Analysis Area Under Curve Arthritis Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - pathology Atherosclerosis Biomarkers - analysis Blood C-reactive protein Cardiovascular diseases Coronary Artery Disease - etiology Coronary Artery Disease - pathology Cross-Sectional Studies Diagnosis Female Glycoproteins Health aspects Humans Inflammation Magnetic Resonance Spectroscopy - methods Male Medical examination Medical research Medicine, Experimental Middle Aged Rheumatoid factor Risk factors ROC Curve |
| title | Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A14%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20a%20novel%20inflammatory%20marker,%20GlycA,%20for%20assessment%20of%20rheumatoid%20arthritis%20disease%20activity%20and%20coronary%20atherosclerosis&rft.jtitle=Arthritis%20research%20&%20therapy&rft.au=Ormseth,%20Michelle%20J&rft.date=2015-05-09&rft.volume=17&rft.issue=1&rft.spage=117&rft.epage=117&rft.pages=117-117&rft.artnum=117&rft.issn=1478-6354&rft.eissn=1478-6362&rft_id=info:doi/10.1186/s13075-015-0646-x&rft_dat=%3Cgale_pubme%3EA541613711%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1684429775&rft_id=info:pmid/25956924&rft_galeid=A541613711&rfr_iscdi=true |